Further studies were warranted to examine whether LSD1 expression is related to a specific subtype (i.e., basal/squamous) of human urinary bladder cancer and to develop a more potent LSD1 inhibitor for bladder cancer prevention and treatment. Here, KDM1A is linked to urinary bladder carcinoma.